PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · Real-Time Price · USD
21.68
+0.95 (4.58%)
At close: Aug 21, 2026, 4:00 PM EDT
22.17
+0.49 (2.25%)
After-hours: Aug 21, 2026, 7:30 PM EDT
PROCEPT BioRobotics Revenue
PROCEPT BioRobotics had revenue of $94.50M in the quarter ending June 30, 2026, with 19.34% growth. This brings the company's revenue in the last twelve months to $337.34M, up 22.69% year-over-year. In the year 2025, PROCEPT BioRobotics had annual revenue of $308.05M with 37.22% growth.
Revenue (ttm)
$337.34M
Revenue Growth
+22.69%
P/S Ratio
3.68
Revenue / Employee
$379,889
Employees
888
Market Cap
1.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 308.05M | 83.56M | 37.22% |
| Dec 31, 2024 | 224.50M | 88.31M | 64.84% |
| Dec 31, 2023 | 136.19M | 61.18M | 81.55% |
| Dec 31, 2022 | 75.01M | 40.54M | 117.60% |
| Dec 31, 2021 | 34.47M | 26.76M | 346.72% |
| Dec 31, 2020 | 7.72M | 1.55M | 25.09% |
| Dec 31, 2019 | 6.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.67B |
| Enovis | 2.30B |
| Integra LifeSciences Holdings | 1.65B |
| CONMED | 1.37B |
| Lumexa Imaging Holdings | 1.04B |
| Tandem Diabetes Care | 1.04B |
| Alphatec Holdings | 815.05M |
| Bioventus | 581.85M |
PRCT News
- 4 days ago - Kaplan Fox Advises PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Act Before the Lead Plaintiff Deadline on September 22, 2026 - GlobeNewsWire
- 6 days ago - PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026 - GlobeNewsWire
- 12 days ago - PRCT Shareholders Have Rights - If You Lost Money Investing in PROCEPT BioRobotics Corporation Contact Robbins LLP for Information About Recovering Your Losses - PRNewsWire
- 12 days ago - PRCT Investor Announcement: PROCEPT BioRobotics Sued on behalf of Investors to Recover Losses after Artificially Inflated Revenue Leads to 18% Stock Drop - PRNewsWire
- 13 days ago - Kaplan Fox Notifies PROCEPT BioRobotics Corporation (PRCT) Investors of an Upcoming Lead Plaintiff Deadline on September 22, 2026 - Newsfile Corp
- 18 days ago - Procept BioRobotics management to meet with Piper Sandler - TheFly
- 18 days ago - Kaplan Fox Urges PROCEPT BioRobotics Corporation (PRCT) Investors Seeking Recovery to Contact the Firm Before September 28, 2026 - Newsfile Corp
- 18 days ago - Procept BioRobotics price target lowered to $23 from $30 at Evercore ISI - TheFly